Chemomab Therapeutics Ltd Net Income
| CMMB Stock | USD 1.51 0.03 2.03% |
As of the 13th of February 2026, Chemomab Therapeutics shows the risk adjusted performance of (0.13), and Mean Deviation of 3.51. Chemomab Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Chemomab Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Chemomab Therapeutics' valuation are provided below:We have found one hundred twenty available fundamental signals for Chemomab Therapeutics Ltd, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Chemomab Therapeutics Ltd prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of February 13, 2026, Market Cap is expected to decline to about 18.1 M. In addition to that, Enterprise Value is expected to decline to about 20.4 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -12.6 M | -13.2 M | |
| Net Loss | -12.6 M | -13.2 M | |
| Net Loss | -24.9 M | -23.6 M | |
| Net Loss | (2.80) | (2.94) | |
| Net Income Per E B T | 0.88 | 1.02 |
Chemomab | Net Income | Build AI portfolio with Chemomab Stock |
Analyzing Chemomab Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Chemomab Therapeutics's current valuation and future prospects.
Latest Chemomab Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Chemomab Therapeutics Ltd over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Chemomab Therapeutics financial statement analysis. It represents the amount of money remaining after all of Chemomab Therapeutics Ltd operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Chemomab Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Chemomab Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (14.01 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Chemomab Net Income Regression Statistics
| Arithmetic Mean | (5,115,381) | |
| Geometric Mean | 10,403,255 | |
| Coefficient Of Variation | (284.04) | |
| Mean Deviation | 9,701,401 | |
| Median | (6,002,000) | |
| Standard Deviation | 14,529,688 | |
| Sample Variance | 211.1T | |
| Range | 54.8M | |
| R-Value | (0.43) | |
| Mean Square Error | 183.5T | |
| R-Squared | 0.19 | |
| Significance | 0.08 | |
| Slope | (1,238,437) | |
| Total Sum of Squares | 3377.8T |
Chemomab Net Income History
Other Fundumenentals of Chemomab Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Chemomab Therapeutics Net Income component correlations
Chemomab Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Chemomab Therapeutics is extremely important. It helps to project a fair market value of Chemomab Stock properly, considering its historical fundamentals such as Net Income. Since Chemomab Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Chemomab Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Chemomab Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. Projected growth potential of Chemomab fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Chemomab Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Chemomab Therapeutics's market price often diverges from its book value, the accounting figure shown on Chemomab's balance sheet. Smart investors calculate Chemomab Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Chemomab Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Chemomab Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Chemomab Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Chemomab Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Chemomab Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Chemomab Therapeutics.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Chemomab Therapeutics on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Chemomab Therapeutics Ltd or generate 0.0% return on investment in Chemomab Therapeutics over 90 days. Chemomab Therapeutics is related to or competes with Kazia Therapeutics, Theriva Biologics, Elevai Labs, Can Fite, Biovie, XORTX Therapeutics, and InMed Pharmaceuticals. Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of i... More
Chemomab Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Chemomab Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Chemomab Therapeutics Ltd upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.19) | |||
| Maximum Drawdown | 21.53 | |||
| Value At Risk | (7.21) | |||
| Potential Upside | 7.74 |
Chemomab Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Chemomab Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Chemomab Therapeutics' standard deviation. In reality, there are many statistical measures that can use Chemomab Therapeutics historical prices to predict the future Chemomab Therapeutics' volatility.| Risk Adjusted Performance | (0.13) | |||
| Jensen Alpha | (0.92) | |||
| Total Risk Alpha | (1.18) | |||
| Treynor Ratio | (0.41) |
Chemomab Therapeutics February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.40) | |||
| Mean Deviation | 3.51 | |||
| Coefficient Of Variation | (583.82) | |||
| Standard Deviation | 4.51 | |||
| Variance | 20.35 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (0.92) | |||
| Total Risk Alpha | (1.18) | |||
| Treynor Ratio | (0.41) | |||
| Maximum Drawdown | 21.53 | |||
| Value At Risk | (7.21) | |||
| Potential Upside | 7.74 | |||
| Skewness | 0.3004 | |||
| Kurtosis | (0.04) |
Chemomab Therapeutics Backtested Returns
Chemomab Therapeutics secures Sharpe Ratio (or Efficiency) of -0.17, which signifies that the company had a -0.17 % return per unit of standard deviation over the last 3 months. Chemomab Therapeutics Ltd exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Chemomab Therapeutics' risk adjusted performance of (0.13), and Mean Deviation of 3.51 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.89, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Chemomab Therapeutics will likely underperform. At this point, Chemomab Therapeutics has a negative expected return of -0.77%. Please make sure to confirm Chemomab Therapeutics' potential upside, day median price, and the relationship between the total risk alpha and accumulation distribution , to decide if Chemomab Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.65 |
Good predictability
Chemomab Therapeutics Ltd has good predictability. Overlapping area represents the amount of predictability between Chemomab Therapeutics time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Chemomab Therapeutics price movement. The serial correlation of 0.65 indicates that roughly 65.0% of current Chemomab Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.65 | |
| Spearman Rank Test | 0.57 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Chemomab Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Chemomab Therapeutics Ltd reported net income of (14.01 Million). This is 104.11% lower than that of the Biotechnology sector and 120.0% lower than that of the Health Care industry. The net income for all United States stocks is 102.45% higher than that of the company.
Chemomab Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Chemomab Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Chemomab Therapeutics could also be used in its relative valuation, which is a method of valuing Chemomab Therapeutics by comparing valuation metrics of similar companies.Chemomab Therapeutics is currently under evaluation in net income category among its peers.
Chemomab Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Chemomab Therapeutics from analyzing Chemomab Therapeutics' financial statements. These drivers represent accounts that assess Chemomab Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Chemomab Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 71.6M | 36.4M | 6.0M | 32.5M | 29.2M | 18.1M | |
| Enterprise Value | 57.2M | 23.1M | (2.9M) | 26.7M | 24.1M | 20.4M |
Chemomab Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Chemomab Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Chemomab Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Chemomab Therapeutics' value.| Shares | Advisory Services Network, Llc | 2024-03-31 | 0.0 |
Chemomab Fundamentals
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | (577.12 K) | ||||
| Shares Outstanding | 6.16 M | ||||
| Shares Owned By Insiders | 14.05 % | ||||
| Shares Owned By Institutions | 11.88 % | ||||
| Number Of Shares Shorted | 16.75 K | ||||
| Price To Book | 0.84 X | ||||
| EBITDA | (13.96 M) | ||||
| Net Income | (14.01 M) | ||||
| Cash And Equivalents | 51.72 M | ||||
| Cash Per Share | 4.53 X | ||||
| Total Debt | 324 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.48 X | ||||
| Book Value Per Share | 1.82 X | ||||
| Cash Flow From Operations | (15.46 M) | ||||
| Short Ratio | 0.26 X | ||||
| Earnings Per Share | (1.44) X | ||||
| Target Price | 17.5 | ||||
| Beta | 0.59 | ||||
| Market Capitalization | 9.73 M | ||||
| Total Asset | 16.96 M | ||||
| Retained Earnings | (102.62 M) | ||||
| Working Capital | 12.82 M | ||||
| Net Asset | 16.96 M |
About Chemomab Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Chemomab Therapeutics Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chemomab Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chemomab Therapeutics Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Chemomab Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chemomab Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chemomab Therapeutics Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chemomab Therapeutics Ltd Stock:Check out You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. Projected growth potential of Chemomab fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Chemomab Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Chemomab Therapeutics's market price often diverges from its book value, the accounting figure shown on Chemomab's balance sheet. Smart investors calculate Chemomab Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Chemomab Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Chemomab Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Chemomab Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.